Testing BL-ARC002 for advanced solid tumors
Part of Cancer clinical trials.
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of advanced or metastatic solid tumor that did not respond to standard treatment
- Your cancer has at least one measurable lesion (tumor) visible on imaging
- You are in good enough health to do light daily activities (ECOG 0-1)
- Your heart, kidney, and liver function are adequate, and your blood clotting is normal
- You have recovered from side effects of prior cancer treatments to mild levels or none
- You are willing to provide a tumor tissue sample from the past 2 years for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called BL-ARC002 for people with advanced or metastatic cancers of the esophagus, stomach, colon, rectum, or other solid tumors. The goal is to see if it is safe and effective in treating these cancers.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.